Search hospitals > Nevada > Henderson
GenesisCare USA - Henderson
Claim this profileHenderson, Nevada 89074
Global Leader in Cancer
Global Leader in Adenocarcinoma
Conducts research for Breast Cancer
Conducts research for Tumors
Conducts research for Leukemia
103 reported clinical trials
2 medical researchers
Summary
GenesisCare USA - Henderson is a medical facility located in Henderson, Nevada. This center is recognized for care of Cancer, Adenocarcinoma, Breast Cancer, Tumors, Leukemia and other specialties. GenesisCare USA - Henderson is involved with conducting 103 clinical trials across 281 conditions. There are 2 research doctors associated with this hospital, such as John A. Ellerton and Alan K. Ikeda.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Adenocarcinoma
Global LeaderStage IV
Stage II
Stage III
Top PIs
John A. EllertonOptumCare Cancer Care at Fort Apache4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
147 reported clinical trials
225 drugs studied
Alan K. IkedaAlliance for Childhood Diseases/Cure 4 the Kids Foundation7 years of reported clinical research
Expert in Tumors
Expert in Leukemia
52 reported clinical trials
109 drugs studied
Clinical Trials running at GenesisCare USA - Henderson
Breast Cancer
Bladder Cancer
Non-Small Cell Lung Cancer
Bladder Carcinoma
Lung Cancer
Cancer
Gastric Cancer
Renal Cell Carcinoma
Esophageal Cancer
Anal Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Mobile Health
for Breast Cancer
This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the WiseBag, to monitor medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor. To ensure CDK4/6 inhibitors achieve their full clinical benefit, patients need to take them as prescribed, following a complex treatment schedule. Forgetfulness was the most common reason reported for medication non adherence. Using the WiseBag along with CONCURxP or enhanced usual care may improve medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor.
Recruiting1 award N/A10 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at GenesisCare USA - Henderson?
GenesisCare USA - Henderson is a medical facility located in Henderson, Nevada. This center is recognized for care of Cancer, Adenocarcinoma, Breast Cancer, Tumors, Leukemia and other specialties. GenesisCare USA - Henderson is involved with conducting 103 clinical trials across 281 conditions. There are 2 research doctors associated with this hospital, such as John A. Ellerton and Alan K. Ikeda.